



Plenary sitting

B8-1412/2016

3.1.2017

MOTION FOR A RESOLUTION

pursuant to Rule 133 of the Rules of Procedure
on an effective treatment for Alzheimer's disease

Mireille D'Ornano

Motion for a European Parliament resolution on an effective treatment for Alzheimer's disease

The European Parliament,

- having regard to Article 168 of the Treaty on the Functioning of the European Union,
- having regard to Rule 133 of its Rules of Procedure,
- A. whereas, according to the World Health Organisation, 36 million people worldwide have dementia (2010), most of whom suffer from Alzheimer's disease;
- B. whereas, according to a study published on 31 August 2016, the 'aducanumab' preventative treatment, which targets beta-amyloid and was developed by Biogen, proved partially effective in the phase I clinical trials carried out on 165 participants, but whereas before now, potential treatments for Alzheimer's disease that target beta-amyloid have either proved ineffective or caused serious side effects;
- C. whereas a study published on 9 December 2016 (*The Lancet*), which was conducted by Sweden's Karolinska Institute and consisted of a phase I clinical trial in which 30 patients were administered a vaccine that targets the tau protein, concluded that the vaccine is likely to prove effective, and whereas other vaccines and treatments are being developed;
- 1. Urges the Commission to support European research into a treatment, and especially a vaccine, for Alzheimer's disease, and innovative therapeutic treatments such as those mentioned in recital C.